

Cadila Healthcare Ltd. - Consolidated Gross Sales Break-up

Rs. Mio.	Q2 14-15	Q2 13-14	% Gr y-y	YTD 14-15	YTD 13-14	% Gr y-y
Domestic	8,835	7,997	10.5%	17543	16093	9.0%
Formulations	6,808	6,263	8.7%	13,557	12,515	8.3%
API	257	119	115.6%	497	319	55.8%
Wellness	1,101	1,039	5.9%	2,176	2,189	-0.6%
Animal Health & Others	669	576	16.2%	1,313	1,070	22.7%
Exports	11,093	8,310	33.5%	21,763	15,370	41.6%
Formulations	10,331	7,438	38.9%	20,102	13,710	46.6%
US	8,020	4,786	67.6%	15,185	8,605	76.5%
Europe	777	942	-17.5%	1,789	1,870	-4.3%
Japan	2	131	-98.3%	2	252	-99.2%
Latin America	647	654	-1.1%	1,191	1,177	1.2%
Emerging Mkts & Others	885	925	-4.3%	1,936	1,806	7.2%
API	630	738	-14.6%	1,397	1,396	0.1%
Animal Health & Others	132	134	-1.6%	264	264	0.1%
JVs & Alliances	1,136	1,068	6.4%	2,325	2,375	-2.1%
Total	21,064	17,375	21.2%	41,631	33,838	23.0%

Cadila Healthcare Ltd.

Details of other incomes

Rs. Mio.	Q2 14-15	Q2 13-14	% Gr y-y	YTD 14-15	YTD 13-14	% Gr y-y
Other Operating Income	445	486	-8.5%	742	782	-5.1%
Royalty Income	229	74	209.5%	289	175	65.1%
Net Gain on foreign currency transactions and translation (Refer Note below)	-18	175	-110.0%	3	175	-98.1%
Others	233	236	-1.4%	450	431	4.3%

Note : Apart from this loss, there was a net gain of Rs. 16 Mio. in Q2 14-15 on translation of inventories held by foreign subsidiaries, which has been included in Cost of Goods. Thus, on aggregate level, there was a loss of Rs. 2 Mio. on operating transactions (above EBIDTA line) in Q2 14-15 vs loss of Rs. 4 Mio. in Q2 13-14. See details below for more clarity.

Rs. Mio.	Q2 14-15	Q2 13-14	% Gr y-y	YTD 14-15	YTD 13-14	% Gr y-y
Other Income	146	122	19.4%	250	248	1.0%
Interest & Dividend income	107	85	25.6%	192	179	6.8%
Profit on sale of investments	23	9	153.4%	27	37	-27.5%
Profit on sale of assets	0	0		0	0	
Others	16	28	-43.0%	32	32	1.2%

Details of Foreign Exchange Fluctuations

Rs. Mio. (+ = loss, - = gain)	Q2 14-15	Q2 13-14	% Gr y-y	YTD 14-15	YTD 13-14	% Gr y-y
A. On operating transactions (above EBIDTA line)	2	4	-50.0%	-46	-245	81.2%
a. Included in other income	18	-210	108.6%	-3	-175	98.3%
b. Included in sales	0	271	-100.0%	0	327	-100.0%
c. Included in cost of goods	-16	-57	71.9%	-43	-397	89.2%
B. On Foreign Currency Borrowings (part of interest cost)	12	-125	109.5%	-1	-144	99.1%
Total Foreign Currency Fluctuations (+ = loss, - = gain)	14	-121	111.5%	-47	-389	87.8%

Details of R&D Expenses

Rs. Mio.	Q2 14-15	Q2 13-14	% Gr y-y	YTD 14-15	YTD 13-14	% Gr y-y
Total R&D Expenses	1,179	1,288	-8.5%	2,235	2,341	-4.5%

Consolidated Capex for Apr-Sep 14

Rs. 1726
Mio.

R&D capex included in above for Apr-Sep 14

Rs. 97
Mio.